Japanese phase II study of90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma-Reference-Cited by-同舟云学术

Japanese phase II study of90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma

Published:2009-01 Issue:1 Volume:100 Page:158-164
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:

Author:

Tobinai Kensei,Watanabe Takashi,Ogura Michinori,Morishima Yasuo,Hotta Tomomitsu,Ishizawa Kenichi,Itoh Kuniaki,Okamoto Shin-ichiro,Taniwaki Masafumi,Tsukamoto Norifumi,Okumura Hirokazu,Terauchi Takashi,Nawano Shigeru,Matsusako Masaki,Matsuno Yoshihiro,Nakamura Shigeo,Mori Shigeo,Ohashi Yasuo,Hayashi Masaki,Endo Keigo

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2008.00999.x/fullpdf

Reference28 articles.

1. Stage I and II non-Hodgkin's lymphomas: long-term results of radiation therapy;Reddy;Int J Radiat Oncol Biol Phys,1989

2. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University;MacManus;J Clin Oncol,1996

3. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program;McLaughlin;J Clin Oncol,1998

4. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study;Igarashi;Ann Oncol,2002

5. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group;Hiddemann;Blood,2005

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study;Annals of Hematology;2023-03-30

2. The standardized uptake value calculated from ¹¹¹In-ibritumomab tiuxetan single-photon emission computed tomography/computed tomography is a useful predictor of the clinical response in patients treated by ⁹⁰Y- ibritumomab tiuxetan therapy;Journal of Clinical and Experimental Hematopathology;2021

3. Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: a single-institution experience;Hematology;2019-01-01

4. Safety of ⁹⁰Y-ibritumomab Tiuxetan Treatment for Japanese Patients in Real-world Clinical Practice;YAKUGAKU ZASSHI;2019-01-01

5. Tumor long-axis diameter and SUVmax predict long-term responders in 90Y-ibritumomab tiuxetan monotherapy;International Journal of Hematology;2018-09-10